drugset / Trial / NCT01236690

Study of Hepatoma Treated by Perfusing Cinobufacin Through Hepatic Artery Combining Embolotherapy

NCT01236690 ↗

Phase 2 Unknown 284 enrolled Changhai Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

Cinobufacini has the effects of anticancer, improving the liver function, elevation of immunity and little side effects, and is important and significant for the patients with hepatitis, liver cirrhosis and hepatomas. Compared with transarterial chemoembolization (TACE) , the clinical effect of cinobufacini is non-inferior/ equivalent.Compared with TACE, cinobufacini is superior in security .

Timeline

Start
2010-11
Primary completion
2013-10
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Cinobufacin Unknown — Other